Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 109

Results For "India"

3569 News Found

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr
News | August 09, 2025

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr

Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25


Sigachi begins construction work for MCC capacity expansion at Dahej
News | August 08, 2025

Sigachi begins construction work for MCC capacity expansion at Dahej

With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA


ekincare launches elva.AI to resolve 80% of employee healthcare queries
Digitisation | August 08, 2025

ekincare launches elva.AI to resolve 80% of employee healthcare queries

Currently focused on platform-related queries, elva.AI is the first step in ekincare’s broader roadmap


Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
News | August 06, 2025

Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%

The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter


Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines
News | August 06, 2025

Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines

Vasograin Plus represents a major advancement in the treatment of migraine


Aster DM Healthcare to build Rs. 580 crore crore hospital in Bengaluru
Healthcare | August 05, 2025

Aster DM Healthcare to build Rs. 580 crore crore hospital in Bengaluru

This will be Aster’s fifth hospital in Bengaluru


Eli Lilly inaugurates global capability centre in hyderabad to advance AI initiatives
Digitisation | August 05, 2025

Eli Lilly inaugurates global capability centre in hyderabad to advance AI initiatives

The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery


GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr
News | August 03, 2025

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr

The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results